The dollar's rebound strengthens European exporters as earnings season peaks. The euro has fallen over 5% against the greenback this year, benefiting firms with overseas revenue. A UBS basket of dollar-exposed stocks like Novo Nordisk, Diageo, GSK, and Rentokil Initial rallied 8% this month, the most since July 2022.
Companies representing nearly 40% of the Stoxx 600's market cap are reporting this week and next. A weaker euro could add about 3.1 percentage points to regional earnings growth, according to HSBC strategists. Strategists note the currency impact may not be fully priced in, offering a potential boost to sectors with subdued earnings expectations.
European healthcare, generating 40% of revenue in the US, stands to gain significantly, with Oddo BHF estimating a 2.5%-3.5% EPS boost for Novo Nordisk and 2%-3% at Sanofi. Both report within two weeks. However, currency benefits are not universal; Adidas and Puma face margin pressure from dollar-denominated Asian sourcing.
For the broader market, euro strength has historically driven MSCI Europe outperformance, benefiting domestically exposed financials. Sustained euro weakness could raise caution for southern Europe's domestic-focused banks. At the individual stock level, hedging complexity can delay or mute exporter benefits, making currency a risk to manage rather than an investment thesis.
Source: Bloomberg Markets · Summarized by HeadlinesBriefing